- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Alberto Ascherio Discusses Vitamin D and MS
Alberto Ascherio, MD, DrPh, professor of epidemiology and nutrition at the Harvard T. H. Chan School of Public Health and professor of medicine at the Harvard Medical School, discusses the role of vitamin D insufficiency in the risk of multiple sclerosis (MS) and the optimal dose of vitamin D for patients with MS.
Alberto Ascherio, MD, DrPh, professor of epidemiology and nutrition at the Harvard T. H. Chan School of Public Health and professor of medicine at the Harvard Medical School, discusses the role of vitamin D insufficiency in the risk of multiple sclerosis (MS) and the optimal dose of vitamin D for patients with MS.
Transcript
What role does vitamin D insufficiency have in MS risk, and has an optimal vitamin D dose been established?
Individuals with low vitamin D levels have a higher risk of MS. It’s about a two-fold higher risk in people who are vitamin D deficient as compared to people with optimal levels. It has not been determined in a final way, but I think it's pretty reasonable to think about 3000, around 3000 iu per day of oral vitamin D3 would probably be sufficient for the large majority of patients. It’s a dose that would increase the level of vitamin D from a median of 50 nmol/L, which is what we find the European patient with MS, to close to 100 nmol/L, which is the level that you find associated with optimal outcome in MS.
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More
